Cargando…
Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
BACKGROUND: Hepatic steatosis is a common form of cystic fibrosis associated liver disease (CFLD) seen in an estimated 15%-60% of patients with cystic fibrosis (CF). The pathophysiology and health implications of hepatic steatosis in cystic fibrosis remain largely unknown. In the general population,...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960296/ https://www.ncbi.nlm.nih.gov/pubmed/31966908 http://dx.doi.org/10.4254/wjh.v11.i12.761 |